TY - JOUR
T1 - Management of Peanut Allergy
AU - Venter, Carina
AU - Sicherer, Scott H.
AU - Greenhawt, Matthew
N1 - Funding Information:
Conflicts of interest: C. Venter has received honorariums for lectures provided for Danone, Mead Johnson, Nestle, and Abbott Laboratories; and received research support from Thermofisher. S. H. Sicherer reports royalty payments from UpToDate and from Johns Hopkins University Press; grants to his institution from the National Institute of Allergy and Infectious Diseases, from Food Allergy Research and Education, and from HAL Allergy; and personal fees from the American Academy of Allergy, Asthma and Immunology (Deputy Editor of Journal of Allergy and Clinical Immunology: In Practice), outside of the submitted work. M. Greenhawt is supported by grant #5K08HS024599-02 from the Agency for Healthcare Quality and Research; is an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Nutricia, Kaleo Pharmaceutical, Nestle, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Before Brands, multiple state allergy societies, the American College of Allergy Asthma and Immunology, and the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters.
Publisher Copyright:
© 2018 American Academy of Allergy, Asthma & Immunology
PY - 2019/2
Y1 - 2019/2
N2 - Peanut allergy is a growing public health concern in westernized countries. Peanut allergy is characterized as an often severe and lifelong allergy, which can have detrimental effects on quality of life and trigger anxiety. Although multiple therapeutic options are emerging, the focus of current management strategies is strict peanut avoidance and carriage of self-injectable epinephrine. The greatest risk of reacting to peanut comes from direct ingestion, whereas casual skin contact or airborne exposure is highly unlikely to provoke significant symptoms. Patients and families must be educated about how to best execute strict peanut avoidance through careful label reading as well as how to understand and address likely and unlikely risk with regard to peanut exposure in public, in particular when dining outside of the home and for children attending school or child care. This review discusses the risk of exposure in public such as at school or on an airplane and how such risk can be abated, situations and scenarios when dining out of the house that may pose more risks than others, the essentials of US and EU label reading laws with particular emphasis on precautionary labeling and the risk implied by such, quality of life and psychosocial issues that may affect the peanut allergic individual and family, and a discussion of how risk may differ and evolve based on the patient's age.
AB - Peanut allergy is a growing public health concern in westernized countries. Peanut allergy is characterized as an often severe and lifelong allergy, which can have detrimental effects on quality of life and trigger anxiety. Although multiple therapeutic options are emerging, the focus of current management strategies is strict peanut avoidance and carriage of self-injectable epinephrine. The greatest risk of reacting to peanut comes from direct ingestion, whereas casual skin contact or airborne exposure is highly unlikely to provoke significant symptoms. Patients and families must be educated about how to best execute strict peanut avoidance through careful label reading as well as how to understand and address likely and unlikely risk with regard to peanut exposure in public, in particular when dining outside of the home and for children attending school or child care. This review discusses the risk of exposure in public such as at school or on an airplane and how such risk can be abated, situations and scenarios when dining out of the house that may pose more risks than others, the essentials of US and EU label reading laws with particular emphasis on precautionary labeling and the risk implied by such, quality of life and psychosocial issues that may affect the peanut allergic individual and family, and a discussion of how risk may differ and evolve based on the patient's age.
KW - Allergen avoidance
KW - Anaphylaxis
KW - Epinephrine
KW - Epinephrine auto-injector
KW - Food allergy
KW - Food allergy labeling
KW - Peanut allergy
KW - Peanut allergy management
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85058578112&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2018.10.043
DO - 10.1016/j.jaip.2018.10.043
M3 - Article
C2 - 30717865
AN - SCOPUS:85058578112
SN - 2213-2198
VL - 7
SP - 345-355.e2
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 2
ER -